Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
Table 1
Characteristics of epithelial ovarian cancer patients with neoadjuvant chemotherapy.
Characteristic
All population (n = 27)
Stage III (n = 12)
Stage IV (n = 15)
value
Pre-NACT
Median age at diagnosis [IQR], years
65 [59–70]
64 [58–65]
66 [62–74]
0.249
Median body mass index [IQR], kg/m2
26 [23.4–29.7]
28.2 [22–32.7]
25.9 [23.4–28.6]
0.354
Germline BRCA1/2 mutation, n (%)
1/19 (5)
1/8 (13)
0/11 (0)
—
Procedures with (+) cytology, n (%)
Paracentesis
15/15 (100)
10/10 (100)
5/5 (100)
—
Thoracentesis
6/6 (100)
0 (0)
6/6 (100)
—
Median volume of paracentesis [IQR], mL
3000 [1600–5600]
3500 [1500–6025]
2600 [1450–4550]
—
Median volume of thoracentesis [IQR], mL
1500 [950–1700]
NA
1500 [950–1700]
—
NACT
Median time from diagnosis to NACT [IQR], days
26 [19–33]
29 [20–34]
25 [15–36]
0.680
Median NACT cycles, (range)
3 (3–6)
3 (3–4)
4 (3–6)
0.080
Cycles of NACT, n (%)
3 cycles
16 (59)
9 (75)
7 (47)
—
4 cycles
7 (26)
3 (25)
4 (27)
—
6 cycles
4 (15)
0 (0)
4 (27)
—
NACT response
Hypoalbuminemia,n (%)
Before NACT
10 (37)
5 (41.7)
5 (33.3)
0.656
After NACT
1 (4)
0 (0.0)
1 (6.7)
1.000
Median CA-125 [IQR], U/mL
Before NACT
1077 [500–3317]
993 [297–3124]
1168 [707–3460]
0.661
After NACT
20.4 [11–69]
21 [12–68]
19 [8–70]
0.464
Radiographic response to NACT, n (%)
Reduction or resolved, omental caking
21/24 (88)
10/11 (91)
11/13 (85)
—
Reduction or resolved, ascites
21/23 (91)
10/11 (91)
11/12 (92)
—
Reduction or resolved, pleural effusion
9/11 (82)
4/4 (100)
5/7 (71)
—
Reduction or resolved, lesions
18/21 (86)
6/9 (67)
12/13 (92)
—
All patients received taxane/platinum chemotherapy with bevacizumab added in 1 patient. Four SIV patients received 6 cycles due to physician preference (n = 3) and coronary artery stent placement postponing surgery (n = 1). Serum albumin levels <3.5 g/dL. Five (42%) SIII and 6 (40%) SIV had abnormal CA-125 levels (>35 U/mL) Post-NACT (range = 36–228 U/mL). IQR: interquartile range; NACT: neoadjuvant chemotherapy.
